The aim of this study was to analyse the incidence and risk factors for cytomegalovirus infection (CMV-I) and disease (CMV-D) after a reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (alloHSCT-RIC). We included 186 consecutive alloHSCT-RIC adult patients at risk for CMV reactivation (patient and/or donor CMV seropositivity). Conditioning regimen was based on fludarabine plus an alkylating agent. For guiding pre-emptive anti-CMV therapy, Pp65 Antigenemia (pp65Ag) (n ¼ 116) or quantitative polymerase chain reaction (quantPCR) (n ¼ 70) were used. The 2-year incidence of CMV-I and/or CMV-D was 36% (11% for CMV-D). Of note, 12/14 (86%) episodes of CMV-D in the pp65Ag group had lung involvement compared with only 3/ 15 (20%) in the quantPCR group (P ¼ 0.01). Importantly, the number of patients who developed CMV pneumonia with prior negative screening tests was unusually high (67% overall). Multivariate analysis of risk factors for CMV-D identified two risk factors: (i) steroid therapy for moderateto-severe graft-vs-host disease (GVHD) (hazard ratio 4.7, P ¼ 0.02); and (ii) alternative donors (non-HLA-identical siblings) [hazard ratio 2.7, P ¼ 0.002]. Our findings suggest that CMV is still a major concern in alloHSCT-RIC. Variables associated with poor anti-CMV T-cell recovery (that is, GVHD and donor type) are helpful in identifying patients at higher risk for CMV-D in the alloHSCT-RIC setting.
Introduction
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (alloHSCT-RIC) is now a consolidated alternative for patients with an indication for alloHSCT but have comorbidities, which discourage a high-dose myeloablative conditioning regimen. RIC regimens may reduce the early post transplant infectious morbidity, 1,2 because of shorter periods of leukopenia and less organ damage. Some authors have also described a reduction of incidence of cytomegalovirus infection (CMV-I) and disease (CMV-D) during the first months after transplant, but with later increases because of graft-vs-host disease (GVHD) and its treatment. 3 However, RIC regimens that include in vivo T-cell depletion with antithymocyte globulin (ATG), and, more importantly, with alemtuzumab, may lead to high incidence of CMV-I after HSCT, but CMV-D may be prevented with close monitorization and pre-emptive anti-CMV therapy. [4] [5] [6] [7] On the other hand, non-T-cell depleted RIC regimens may lead to a high incidence of extensive chronic GVHD and, thus, potentially to a high risk of late (after 3-4 months post-HSCT) CMV-I and CMV-D. Thus, CMV-I and CMV-D may still be a major cause of morbidity and mortality in alloHSCT-RIC setting.
With the aim of decreasing CMV-related morbidity and mortality, several strategies have been developed, although close screening for CMV-I and pre-emptive treatment (before the onset of CMV-D) with ganciclovir, foscarnet and other drugs is the main accepted strategy. [8] [9] [10] Pre-emptive therapy relies on the availability of a sensitive, rapid and specific diagnostic test of CMV-I. Among the available screening techniques to detect CMV replication (infection), the most commonly used are the pp65 antigenemia (pp65Ag) assay, and several qualitative and quantitative polymerase chain reaction (PCR) analyses for CMV DNA or CMV mRNA 9, [11] [12] [13] [14] [15] At our institution, since 1993 all AlloHSCT recipients at risk for developing CMV-I were monitored with the detection of pp65Ag in peripheral blood polymorphonuclear granulocytes. 16 The progressive switch to quantitative PCR (quantPCR) for the diagnosis and follow-up of numerous viral pathogens led to the implementation of a validated quantPCR for monitoring CMV in immunocompromised hosts, and, thus, in late 2003 we switched to a PCR-based pre-emptive therapy. The growing numbers of RIC allografts allowed us to analyse the characteristics of CMV infection and disease as well as the risk factors for CMV-D in a large homogeneous (with respect to the type of conditioning regimen and supportive care) single-centre patient cohort.
Patients and methods

Patients
One hundred and ninety-five consecutive adults received an alloHSCT with a RIC regimen based on fludarabine plus intermediate-dose busulfan or melphalan in our Division between 1999 and 2006. Nine patients (4%) were considered non-evaluable for this study because the patient and donor were CMV seronegative. Detailed characteristics of the 186 evaluable patients are shown in Table 1 . All patients were included in a series of consecutive alloHSCT-RIC trials designed for patients not eligible for a conventional high-dose myeloablative conditioning, as reported elsewhere in detail. [17] [18] [19] All patients gave written informed consent for inclusion in each study, and all studies were approved by our National and local Ethics Committees.
Conditioning regimen and GVHD prophylaxis
In brief, two RIC regimens were used. Both included fludarabine plus either oral busulfan 8-10 mg/kg or IV melphalan 70-140 mg/m 2 (for myeloid and lymphoid malignancies, respectively). 20 There were 35 alternative donor (donors other than HLA-identical siblings) transplants, which included 32 unrelated donor transplants [11 of them were HLA mismatched unrelated donors] and 3 HLA mismatched related donors. Alemtuzumab or ATG were given in recipients of HLA-mismatched related donors or mismatched unrelated donors. One patient with an HLA-mismatched related donor did not receive ATG or alemtuzumab because the MM was in HLA DQB1, whereas the other two had differences in HLA class A or DRB1. Patients with Hodgkin disease with matched unrelated donors (n ¼ 7) received ATG, whereas two patients with chronic lymphocytic leukemia and one with follicular lymphoma with matched unrelated donors received alemtuzumab as part of conditioning. GVHD prophylaxis was described elsewhere. 19, 21 From 1999 until late 2003 it consisted of cyclosporine A (0.5 mg/kg twice daily) plus short-course methotrexate (10 mg/m 2 on days þ 1, þ 3 and þ 6). Since late 2003, we changed to mycophenolate mophetil (MMF) to reduce methotrexate toxicity. MMF was started on day 0 (at least 10 h after the infusion of progenitors) at a dose of 1 g three times daily (15 mg/kg/8 h). MMF was continued until day þ 30 and then tapered if no complete donor T-cell chimerism was achieved or no GVHD was observed. All patients received antimicrobial prophylaxis with acyclovir, fluconazol and norfloxacin or ciprofloxacin during neutropenia and until engraftment.
CMV screening period
All patients at risk were routinely monitored at least twice per week while admitted to the hospital, and thereafter once a week during the first 100 days and monthly until 1 month after the withdrawal of immunosuppression. Patients who developed acute or chronic GVHD were monitored at each outpatient visit (once or twice a week until 1 month after the discontinuation of immunosuppression). /l), weekly heparinized blood samples were tested in all patients for CMV pp65-antigenemia and viremia. CMV antigenemia testing was performed in duplicate as described earlier. 22 Briefly, an indirect immunofluorescence technique was used to detect the presence of any pp65-positive cells. The polymorphonuclear leukocyte fraction was separated from 10 ml of heparinized blood by sedimentation in a 6% dextran solution. A measure of 2 Â 10 5 leukocytes were cytocentrifuged onto glass slides, fixed with 5% formaldehyde for 10 min and air-dried. For staining, a pool of monoclonal antibodies to the CMV pp65-69 polypeptide was used Diagnostics) . This kit contains reagents and enzymes for the specific amplification of a 105 bp region of the CMV genome, and for the direct detection of the specific amplicon. In addition, the kit contains a second heterologous amplification system to identify possible PCR inhibition. External positive controls (Quantitation Standards) allow the determination of the CMV load. The detection limit of this test in combination with the LC 2.0 instrument is consistently 65 copies/ml. Between October 2005 and December 2007, the extraction of CMV DNA was made by affigene DNA extraction kit, Sangtec Molecular Diagnostics AB, Sweden. The PCR was performed by the affigene CMV trender, Sangtec Molecular Diagnostics AB. This kit contains reagents and enzymes for the specific amplification of a region of the CMV genome, and for the direct detection of the specific amplicon. In addition, the kit contains a second heterologous amplification system to identify possible PCR inhibition. Two calibrators, calibrated towards well-characterised and quantitated standard material, enable the quantification of CMV. The detection limit of this test in combination with the M Â 3000P instrument is consistently 180 copies/ml.
Definitions. The level of CMV-I that was established for initiating pre-emptive anti-CMV therapy was defined during the antigenemia period as the presence of a single pp65 antigen-positive cell per 10 5 leukocytes, whereas within the quantPCR period it was defined as 41000 DNA copies/ml in 1 serum sample or 2 consecutive samples with 4500 DNA copies/ml. A recurrent episode of infection was defined as new detection of CMV-I in a patient who had cleared a prior episode for at least 8 weeks. CMV-D was divided into pneumonia, gastrointestinal (GI) disease and retinitis. CMV pneumonia is defined by the presence of signs and/or symptoms of pulmonary disease combined with the detection of CMV in bronchoalveolar lavage fluid or lung tissue samples. Detection of CMV was performed by virus isolation, histopathologic testing, immunohistochemical analysis or in situ hybridisation. CMV GI disease is defined by identification of a combination of clinical symptoms from the upper or lower GI tract, findings of macroscopic mucosal lesions on endoscopy, and demonstration of CMV mucosal infection (by culture, histopathologic testing, immunohistochemical analysis or in situ hybridisation) in a GI tract biopsy specimen. Retinitis was diagnosed by typical lesions observed by an experienced ophthalmologist, without the need for isolation of CMV in the eye fluid. More detailed definitions of CMV-D have been published elsewhere. 23 Pre-emptive therapy Intravenous ganciclovir or foscarnet was started only if CMV antigenemia and/or viremia were detected or when CMV DNA was detected by quantPCR as describe above, at a dose of 5 and 60 mg/kg i.v., respectively, every 12 h for 14 days followed by 5 and 60 mg/kg daily Monday to Friday for 14 days, respectively. Patients with recurrent infection received a second course. Since mid-2003, all outpatients received oral valganciclovir as pre-emptive therapy at a usual dose of 900 mg/twice daily. Hospitalised patients received ganciclovir, reserving foscarnet to patients who developed neutropenia during CMV-I or CMV-D. Patients were considered to have cleared the CMV infection when pp65Ag, viremia were negative or the CMV viral load was undetectable (0 copies/ml) after two consecutive quantPCR tests.
Recurrent episodes of CMV infection were re-treated according to the discretion of the treating physician. For treatment of CMV-D, in addition to anti-CMV drugs, patients with CMV pneumonia also received high-dose intravenous polyvalent immunoglobulins at a dose of 500 mg/kg every other day for 14 days.
Statistical analysis
The main endpoints of the study were to estimate the incidence of CMV-I and CMV-D, and, secondarily, to analyse risk factors for CMV-D in a relatively homogeneous RIC setting and during a post transplant follow-up of at least 1 year in all cases. Overall transplant outcomes were also calculated. The incidences of CMV-I, CMV-D, acute and chronic GVHD, NRM and relapse were calculated using cumulative incidence (Cum Inc) estimates, taking into account the competing risk structure. 24, 25 The probability of OS was estimated from the time of transplantation using Kaplan-Meier curves. 26 Cox regression hazard models were used for univariate and multivariate analyses of risk factors for CMV-D, analysing the impact of post transplant events as time-dependent covariates. Variables that showed an impact on CMV-D in univariate testing but were associated (for example, showed collinearity) with the type of monitoring used (pp65Ag or quantPCR) were not included in the multivariate Cox models, as this could lead to finding 'statistically significant' variables because of chance alone.
Tests of significance were two-sided, with a significance level of Pp0.05. All statistical analyses were performed using SPSS version 15.0 (SPSS, Chicago, IL, USA), with the exception of the cumulative incidence analyses, which were carried out with NCSS 2004 (Number Cruncher Statistical System, Kaysville, UT, USA).
Results
Patient characteristic
Detailed characteristics of patients are shown in Table 1 . There were 63% male, and the median age was 55 years (range, 18-72) with a median follow-up of 17 months (range, 0.25-98). Most patients were transplanted for acute leukemia, and 151/186 received an alloHSCT-RIC from an HLA-identical sibling donor. Conditioning regimen was fludarabine-melphalan in 120 (62%) patients. In vivo T-cell depleting agents such as alemtuzumab (n ¼ 4) and antithymoglogulin (ATG, n ¼ 19) were given in 23 cases (12%) cases. Forty-nine patients developed acute GVHD grade I and 53 grades II-IV (18 grades III-IV). Chronic GVHD was observed in 98 (72%) of 137 evaluable patients.
CMV infection
The details of the episodes of CMV-I and CMV-D are shown in Table 2 . Sixty-nine of 186 patients (37%) monitored developed CMV-I and/or CMV-D during the first 2 years post-alloHSCT-RIC; the 2-year cumulative incidence of CMV-I and/or CMV-D was 36% (95% CI, 30-44%). Forty-four (64%) of 69 patients developed CMV-I without disease with a median onset of 57 days (range, 7-420) ( Table 2 ). The number of patients who developed CMV-I without CMV-D was 9 of 116 (8%) patients monitored with pp65Ag and 35 of 70 (50%) patients with quantPCR, for a 2-year cumulative incidence of 5 and 27%, respectively (Po0.01). Twenty-four (54%) of 44 patients developed more than one episode of CMV-I [20 (28%) in the quantPCR cohort vs 4 (3%) in the pp65Ag cohort, Po0.001]. Thus, the total number of episodes of CMV-I without CMV-D was 75 (17 and 58 in the pp65Ag and quantPCR groups, respectively).
Concerning the efficacy of different pre-emptive anti-CMV drugs, we did not find statistically significant differences in terms of CMV-I resolution rates between Table 2 CMV infection and disease by method of peripheral blood screening used ganciclovir, foscarnet and valganciclovir (87 vs 78% vs 90%, respectively, P ¼ 0.2). Similar efficacy was also observed between patients treated with ganciclovir therapy in the pp65Ag period and valganciclovir in the quantPCR period (88 vs 89%, respectively, P ¼ 0.9).
CMV-D
Twenty-five (13%) patients developed CMV-D (14 patients in the pp65Ag and 11 in the quantPCR cohort) with a median onset of 92 days (range, 26-465) post transplant, for a 2-year cumulative incidence of 11% (95% CI, 7-17%). Three patients developed CMV-D beyond 1-year after transplant (1 patient in the pp65Ag and 2 in the quantPCR period). As shown in Table 2 , a total of 29 CMV-D episodes were diagnosed (14 patients in the pp65Ag and 15 in the quantPCR period), as four patients monitored with quantPCR developed two episodes of CMV-D). CMV pneumonia occurred in 15 of the 29 episodes of CMV-D, in the context of disseminated disease in 3 cases and as isolated CMV pneumonia in the other 12 cases. Of note, 12/14 (86%) episodes of CMV-D, which occurred during the pp65Ag period, had lung involvement, whereas this occurred in only 3/15 (20%) episodes in the quantPCR group (P ¼ 0.01).
Of the 29 cases of CMV-D, 16 (55%) had negative results of the CMV peripheral blood screening results in the 15 days before onset of CMV-D, which was more commonly seen in the pp65Ag cohort [11/14 (78%) in the pp65Ag group and 5/15 (33%) in the quantPCR group (P ¼ 0.04)]. These 16 episodes of CMV-D with negative screening testing occurred at a median interval post transplant of 98 days (range, 26-465). Importantly, the rate of patients who developed CMV pneumonia with negative prior screening tests was unusually high (10/15 cases of CMV pneumonia, 67%), especially in patients monitored with pp65Ag (9/12 (75%) vs 1/3 (33%) in the quantPCR group).
On the other hand, the other 13 cases of CMV-D that occurred in 11 patients developed as a progression of an episode of CMV-I, which was receiving pre-emptive antiviral therapy; these episodes of CMV-D developed at a median interval post transplant of 110 days (range, 31-374). Thus, of the 55 patients who developed an episode of CMV-I (that is, had a positive pp65Ag or a quantPCR screening test) and were started on anti-CMV pre-emptive therapy, 11 (20%) progressed to CMV-D (as 13 episodes of progressive CMV-D occurred in 88 episodes of CMV-I, the rate of progression of CMV-I episodes to CMV-D episodes was 15%). When we compared the characteristics of these 11 patients with those who had CMV-I without CMV-D (n ¼ 44), we found that 7 of the 11 (63%) patients with progression vs 12 of 44 (27%) patients without progression had lymphopenia at day þ 30 after transplant (P ¼ 0.03).
Of the 13 episodes of progressive CMV-D, 8 developed during the first week after the first positive screening test and the start of pre-emptive ani-CMV therapy (median 3 days; range, 2-6), whereas 5 progressed to CMV-D after at least 7 days of pre-emptive induction therapy (median 14 days; range, 9-21). Thus, failure of pre-emptive antiviral therapy (and possible CMV resistance) occurred in 5/88 (5.5%) episodes of CMV-I (5/80 episodes treated with at least 7 days of pre-emptive therapy).
Four of the 29 episodes of CMV-D were not treated (2 with concomitant GI and lung involvement and 2 with isolated CMV pneumonia) as CMV-D was diagnosed only at autopsy and CMV-I was not identified pre-mortem because of false negative CMV blood screening tests; all 4 patients had been screened with pp65Ag. The other 25 cases of CMV-D were diagnosed and treated before death, but seven (28%) died because of CMV-D, 6 of them with isolated CMV pneumonia and one with disseminated CMV-D. Thus, the 2-year rate of CMV-related mortality was 6% (11/186), 7% (8/116) in the pp65Ag group and 4% (3/70) in the quantPCR cohort. When we compared the CMV-D response rates from both screening periods, we observed higher response rates in the quantPCR group (80 vs 43%, P ¼ 0.05). This finding is probably explained by the low response rate in cases with CMV pneumonia (4/11 responses, 36%), which was more common in the pp65 patient cohort, as opposed to a response rate of 92% (12/13 cases) in cases with GI disease and 2/2 cases of retinitis. Table 3 shows the univariate and multivariate analysis of risk factors for CMV-D. In univariate analysis, several variables increased the risk of CMV-D. However, the use of in vivo T-cell depletion with ATG or alemtuzumab and use of MMF as GVHD prophylaxis were clearly associated (that is, showed collinearity) with alternative donors (non-HLA-identical siblings), and, in the final multivariate model only this latter variable and requiring high-dose steroids for moderate-to-severe GVHD were shown to have an impact on CMV-D. Patients who had none of these risk factors (n ¼ 80) had a 2-year incidence of CMV-D of 2% (95% CI, 0.1-5%), those with one risk factor (n ¼ 86) had an incidence of 18% (95% CI, 11-29%), and those with both risk factors (n ¼ 20) had an incidence of 30% (95% CI, 10-50%) [Po0.01]. These risk factors were equally predictive in the pp65Ag cohort (3, 19 and 33%, respectively) and in the quantPCR cohort (0, 15 and 29%, respectively) ( Figure 1 ).
Risk factors for CMV-D
Discussion
In this study, we retrospectively evaluated the characteristics of CMV infection and disease and the risk factors for CMV-D. To avoid the large clinical heterogeneity currently introduced in the practice of alloHSCT, we focused on one specific clinical scenario (that is, alloHSCT-RIC), and did not include in this study conventional high-dose conditioning regimens nor cord blood transplants. 27 In addition, the single-centre nature of the study and analysis of all consecutive patients at risk assure a common supportive care management and applicability of the results to daily practice.
We report an overall incidence of CMV-I and/or disease of 36% in patients who received an alloHSCT-RIC. Since late 2003, with the introduction of the quantPCR for CMV screening, we observed an increase of CMV infection (27% with quantPCR vs 5% pp65Ag test). However, this finding is to a large extent expected, because of a higher sensitivity of PCR techniques than Antigenemia in detecting active viral replication. 7, 14, 15, [28] [29] [30] In addition, relevant changes of patients' characteristics over time led to higher proportion of high-risk patients for CMV-I and CMV-D in the quantPCR period [data not shown], mostly higher proportions of unrelated and mismatched donors (31% in the quantPCR period vs 11% in the pp65Ag period, Po0.01) and in vivo T-cell depleting (20 vs 8%, respectively, Po0.01). 4, 9, 14, 19, 31, 32 Several observations in this study support that CMV infection and disease are still a frequent and serious complication, with a significant incidence of CMV-D (11%), similar to that observed earlier in alloHSCT-RIC patients. 3, 9, 31 Of note, 48% of the cases of CMV-D occurred late post transplant (after day þ 100). In this study, we report a median onset of CMV-I of 57 days, which seems to be delayed compared with RIC regimens based on in vivo T-cell depletion. 4 We also observed that more than half of the patients (24 of 44, 54%) who developed a CMV-I without disease had a recurrence. This observation, in addition to the high rate of late (after day þ 100) episodes of CMV-I and CMV-D (63 and 48%, respectively) have substantial implications. First, patients conditioned without T-cell depletion are expected to have a high incidence of late CMV reactivations, 3 as a high incidence of moderate-to-severe GVHD occurs. It is well know that GVHD and its treatment are major risk factors for CMV disease. 13 Secondly, it seems reasonable to expand the strict virological surveillance, both by increasing the frequency of CMV screening early post-HSCT, and by extending the strict virological surveillance screening after day þ 100 until the T-cell anti-CMV reconstitution occurs.
Another observation that is worth highlighting is the large number of cases of CMV-D with negative recent screening blood tests (16/29, 55%), especially in the Antigenemia period: 11/14 (78%) vs 5/15 episodes (33%) in the quantPCR period. Furthermore, especially relevant are the negative screening results for isolated lung involvement [8/12 episodes (66%) (7/9 in the pp65Ag vs 1/3 in the quantPCR period)] in comparison to only 4/12 (33%) episodes with isolated GI involvement. A higher rate of negative pp65Ag screening tests compared with quantPCR have been reported in cases of CMV colitis, retinitis or other localised non-pulmonary sites of CMV-D. 13, 14, 33, 34 In fact, an advantage in preventing GI CMV-D has been reported with PCR screening techniques in comparison to antigenemia testing. 35 However, as most cases of CMV pneumonia with prior negative screening tests occurred during the pp65Ag screening period in this study, molecular screening methods could offer higher sensitivity over pp65Ag in detecting CMV replication before the occurrence of CMV pneumonia. Nonetheless, this study has important methodological limitations, which are mainly a consequence of its retrospective design.
In our multivariate analysis, the major risk factors associated with CMV-D were the use of steroids for moderate-to-severe GVHD and alternative donors (URDs or mismatched related donors). Both of these variables interfere with T-cell immune reconstitution, especially CMV-specific CD8 þ and CD4 þ T-cells. 36 In this respect, the increased risk of CMV-D found in univariate analysis and the high rate of progression from CMV-I to CMV-D among patients with lymphocytopenia on day þ 30 and/or þ 120 is a marker of the lack of specific anti-CMV immunity at these time points. However, multivariate analysis failed to confirm their impact, surely as we only had the absolute number of lymphocytes or CD4 þ lymphocytes, and not the anti-CMV specific lymphocyte counts. To identify a possible role of ATG or alemtuzumab on the risk of CMV-D, we analysed its risk among patients who did not receive steroids for GVHD (thus, did not develop moderate-to-severe GVHD). Among 95 such patients, 19 developed CMV-I and 5 CMV-D; the rates of these complications among 14 patients who had received ATG or alemtuzumab in the conditioning in comparison to the 81 who had not received any T-cell depletion were 42 vs 6% for CMV-I (P ¼ 0.01) and 21 vs 3% for CMV-D (P ¼ 0.02) (data not shown). These observations are in line with the delay in the anti-CMV T-cell reconstitution produced by these drugs. 37, 38 Currently, every effort should be made to quantify such specific immunity, as all the identified risk factors are merely indirect markers of the lack of specific anti-CMV immune reconstitution. Different techniques have been applied for monitoring of CD8 þ and/or CD4 þ CMV-specific T-cells, mainly by HLArestricted tetramers containing immunodominant peptides from CMV or measurement of peptide-specific intracellular cytokine staining. [39] [40] [41] [42] Unfortunately, such tests are not available at most transplant centres.
In conclusion, these findings suggest that recipients of alloHSCT-RIC have a significant risk of CMV-D, mostly when significant doses of steroids are required for the management of GVHD and in settings that are predictive of delayed anti-CMV T-cell reconstitution (HLA mismatch ± in vivo T-cell depletion to reduce the risk of severe GVHD), irrespective of the type of CMV screening test used (pp65Ag or quantPCR). The observed differences between quantPCR and pp65Ag screening in predicting CMV-D merit further research.
